Head-to-head evidence
Fosphenytoin vs Oxcarbazepine (Oxtellar XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Fosphenytoin
Marketed by Pfizer
NCT00908453 · Phase 3 · completed
The study assigned participants to fosphenytoin dose groups without randomization, blinding, or a comparator arm. Its primary safety endpoint cannot be assessed because the registry does not report results, so the evidence remains limited.
Oxcarbazepine (Oxtellar XR)
Marketed by Supernus Pharmaceuticals
NCT00772603 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fosphenytoin's landscape · Oxcarbazepine (Oxtellar XR)'s landscape